Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Single-Dose, Drug-Drug Interaction Study to Determine the Impact of Co-administration of QPX7728 on the Pharmacokinetics of QPX2014 in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Single-Dose, Drug-Drug Interaction Study to Determine the Impact of Co-administration of QPX7728 on the Pharmacokinetics of QPX2014 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QPX 2014 (Primary) ; Xeruborbactam (Primary)
  • Indications Acinetobacter infections; Bacterial infections; Pseudomonal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Qpex Biopharma

Most Recent Events

  • 23 Aug 2022 According to a Brii Biosciences media release, the company expects to share data from study in the fourth quarter of 2022 at a scientific conference.
  • 20 Dec 2021 Status changed from recruiting to completed.
  • 18 Nov 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top